Increased Liver Fat, Impaired Insulin Clearance, and Hepatic and Adipose Tissue Insulin Resistance in Type 2 Diabetes

Gastroenterology

Volumn 135, Issue 1, 2008, Pages 122-130

  Kotronen, Anna ^a,b   Juurinen, Leena ^a,b   Tiikkainen, Mirja ^a   Vehkavaara, Satu ^a   Yki Järvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; INSULIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CONTROLLED STUDY; FEMALE; GLUCOSE TRANSPORT; HUMAN; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER LEVEL; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 46049089412     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.03.021     Document Type: Article

References (66)

1. Thamer C., Tschritter O., Haap M., et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 37 (2005) 246-251
2. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
3. Perry I.J., Wannamethee S.G., and Shaper A.G. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21 (1998) 732-737
4. Lee D.H., Jacobs Jr. D.R., Gross M., et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 49 (2003) 1358-1366
5. Ohlson L.O., Larsson B., Bjorntorp P., et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 31 (1988) 798-805
6. Hanley A.J., Williams K., Festa A., et al. Insulin resistance atherosclerosis study. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53 (2004) 2623-2632
7. Sattar N., McConnachie A., Ford I., et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 56 (2007) 984-991
8. Kotronen A., Westerbacka J., Bergholm R., et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92 (2007) 3490-3497
9. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 37 (2005) 347-356
10. Kotronen A., Juurinen L., Hakkarainen A., et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31 (2008) 165-169
11. Ferrannini E., Wahren J., Faber O.K., et al. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 244 (1983) E517-E527
12. Meistas M.T., Margolis S., and Kowarski A.A. Hyperinsulinemia of obesity is due to decreased clearance of insulin. Am J Physiol 245 (1983) E155-E159
13. Sonnenberg G.E., Hoffman R.G., Mueller R.A., et al. Splanchnic insulin dynamics and secretion pulsatilities in abdominal obesity. Diabetes 43 (1994) 468-477
14. Peiris A.N., Mueller R.A., Smith G.A., et al. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 78 (1986) 1648-1657
15. Letiexhe M.R., Scheen A.J., Gerard P.L., et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab 77 (1993) 1263-1268
16. Polonsky K.S., Gumbiner B., Ostrega D., et al. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 43 (1994) 871-877
17. Gastaldelli A., Cusi K., Pettiti M., et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133 (2007) 496-506
18. Genuth S.M. Metabolic clearance of insulin in man. Diabetes 21 (1972) 1003-1012
19. Frost D.P., Srivastava M.C., Jones R.H., et al. The kinetics of insulin metabolism in diabetes mellitus. Postgrad Med J 49 Suppl 7 (1973) 949-954
20. Stimmler L., Mashiter K., Snodgrass G.J., et al. Insulin disappearance after intravenous injection and its effect on blood glucose in diabetic and non-diabetic children and adults. Clin Sci 42 (1972) 337-344
21. Orskov H., and Christensen N.J. Plasma disappearance rate of injected human insulin in juvenile diabetic, maturity-onset diabetic and nondiabetic subjects. Diabetes 18 (1969) 653-659
22. Strang B.D., Bertics S.J., Grummer R.R., et al. Relationship of triglyceride accumulation to insulin clearance and hormonal responsiveness in bovine hepatocytes. J Dairy Sci 81 (1998) 740-747
23. Goto T., Onuma T., Takebe K., et al. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 19 (1995) 841-845
24. Kotronen A., Vehkavaara S., Seppala-Lindroos A., et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293 (2007) E1709-E1715
25. Kelley D.E., McKolanis T.M., Hegazi R.A., et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285 (2003) E906-E916
26. Olefsky J.M., Kolterman O.G., and Scarlett J.A. Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am J Physiol 243 (1982) E15-E30
27. Groop L.C., Saloranta C., Shank M., et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 72 (1991) 96-107
28. Turk D., Alzaid A., Dinneen S., et al. The effects of non-insulin-dependent diabetes mellitus on the kinetics of onset of insulin action in hepatic and extrahepatic tissues. J Clin Invest 95 (1995) 755-762
29. Paquot N., Scheen A.J., Dirlewanger M., et al. Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients. Obes Res 10 (2002) 129-134
30. Staehr P., Hother-Nielsen O., Levin K., et al. Assessment of hepatic insulin action in obese type 2 diabetic patients. Diabetes 50 (2001) 1363-1370
31. Basu R., Basu A., Johnson C.M., et al. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes 53 (2004) 2042-2050
32. Alzaid A.A., Dinneen S.F., Turk D.J., et al. Assessment of insulin action and glucose effectiveness in diabetic and nondiabetic humans. J Clin Invest 94 (1994) 2341-2348
33. Lillioja S., Mott D.M., Howard B.V., et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318 (1988) 1217-1225
34. Duckworth W.C., Hamel F.G., and Peavy D.E. Hepatic metabolism of insulin. Am J Med 85 (1988) 71-76
35. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
36. Juurinen L., Tiikkainen M., Hakkinen A.M., et al. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 292 (2007) E829-E835
37. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007) 846-854
38. Ryysy L., Hakkinen A.M., Goto T., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49 (2000) 749-758
39. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87 (2002) 3023-3028
40. Yki-Jarvinen H., Young A.A., Lamkin C., et al. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest 79 (1987) 1713-1719
41. Rizza R.A., Mandarino L.J., and Gerich J.E. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240 (1981) E630-E639
42. Jones C.N., Pei D., Staris P., et al. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 82 (1997) 1834-1838
43. Savage P.J., Flock E.V., Mako M.E., et al. C-Peptide and insulin secretion in Pima Indians and Caucasians: constant fractional hepatic extraction over a wide range of insulin concentrations and in obesity. J Clin Endocrinol Metab 48 (1979) 594-598
44. Thomsen C., Becker U., Winkler K., et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 12 (1994) 487-495
45. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005) E462-E468
46. Westerbacka J., Corner A., Tiikkainen M., et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47 (2004) 1360-1369
47. Sutinen J., Hakkinen A.M., Westerbacka J., et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16 (2002) 2183-2193
48. Lukaski H.C., Johnson P.E., Bolonchuk W.W., et al. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 41 (1985) 810-817
49. Miles J., Glasscock R., Aikens J., et al. A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 24 (1983) 96-99
50. Nurjhan N., Campbell P.J., Kennedy F.P., et al. Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. Diabetes 35 (1986) 1326-1331
51. Groop L.C., Bonadonna R.C., DelPrato S., et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84 (1989) 205-213
52. Campbell P.J., Mandarino L.J., and Gerich J.E. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 37 (1988) 15-21
53. Groop L.C., Bonadonna R.C., Shank M., et al. Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man. J Clin Invest 87 (1991) 83-89
54. Jensen M.D., and Nielsen S. Insulin dose response analysis of free fatty acid kinetics. Metabolism 56 (2007) 68-76
55. Mandarino L.J., Campbell P.J., Gottesman I.S., et al. Abnormal coupling of insulin receptor binding in noninsulin-dependent diabetes. Am J Physiol 247 (1984) E688-E692
56. Thiebaud D., Jacot E., DeFronzo R.A., et al. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 31 (1982) 957-963
57. Wiesenthal S.R., Sandhu H., McCall R.H., et al. Free fatty acids impair hepatic insulin extraction in vivo. Diabetes 48 (1999) 766-774
58. Kashyap S., Belfort R., Gastaldelli A., et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52 (2003) 2461-2474
59. Yki-Jarvinen H., Puhakainen I., Saloranta C., et al. Demonstration of a novel feedback mechanism between FFA oxidation from intracellular and intravascular sources. Am J Physiol 260 (1991) E680-E689
60. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 19 (2005) 471-482
61. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 13 (1992) 415-431
62. Bajaj M., Suraamornkul S., Pratipanawatr T., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52 (2003) 1364-1370
63. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
64. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
65. Monzillo L.U., and Hamdy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 61 (2003) 397-412
66. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495